|January 18, 2013|
|10:58 EDT||JNJ||Earnings Preview: Johnson & Johnson at five-year high ahead of Q4 report |
Johnson & Johnson (JNJ) is scheduled to report Q4 results before the open on Tuesday January 22, with a conference call scheduled for 8:30 am ET. Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide... EXPECTATIONS: Analysts are looking for EPS of $1.17 on revenue of $17.67B, according to First Call. The consensus range for EPS is $1.13-$1.23 on revenue of $17.46B-$17.98B... LAST QUARTER: J&J reported Q3 EPS $1.25 against estimates of $1.21 on revenue of $17.1B against estimates of $16.95B. In its Q3 report, the company gave FY12 EPS guidance of $5.05-$5.10 compared to estimates of $5.06. J&J cited by Remicade, Prezista, Velcade as Q3 growth drivers but noted that Q3 sales were hurt by manufacturing suspension at Doxil/Caelyx supplier. During the Q3 earnings conference call CFO Dominic Caruso said U.S. healthcare utilization rates show early signs of stabilization and U.S. joint reconstruction volumes appear to have improved in the latest data but cautioned that although some positive signs can be seen, it is "still too early to signal any meaningful recovery"... STREET RESEARCH: In the last two months, analysts have been generally positive on J&J. On January 4, Deutsche Bank upgraded Johnson & Johnson to Buy from Hold, citing the company's diversification and expectations the company will see improving trends in 2013. The firm raised its price target for shares to $82 from $75. On December 10, Davenport upgraded the shares to Buy from Neutral with an $80 price target... PRICE ACTION: Shares of Johnson and Johnson are trading near a five-year high of ~$73. The shares rose from around $69 per share to $72.74 on Q3 earnings in October, and have since rallied approximately 5% to $72.94.
News For JNJ From The Last 14 Days
Check below for free stories on JNJ the last two weeks.
|December 5, 2013|
|07:59 EDT||JNJ||Cooper Companies added to Select List at Stifel|
Stifel added Cooper Companies (COO) to its Select List after surveying 36 optometry practices in the U.K. The firm reports that Cooper's new silicone hydrogel daily lens, MyDay, appears to be performing well in the country, and is ranked ahead of J&J's (JNJ) competing TruEye by optometrists there. The firm keeps a $150 price target and Buy rating on Cooper.
|December 4, 2013|
|16:51 EDT||JNJ||Johnson & Johnson unit to pay $1.25M to settle with FDA|
The U.S. Food and Drug Administration has reached a $1.25M settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon, a Johnson & Johnson company, and two of ASP’s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products. The settlement requires ASP to pay $1.2M, company president Bernard Zovighian to pay $30,000, and company VP of quality and regulatory compliance Richard Alberti to pay $20,000. Reference Link
|December 3, 2013|
|08:56 EDT||JNJ||LabCorp announces availability of enhanced HCV GenoSure NS3/4|
Laboratory Corporation (LH) announced the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics’ (JNJ) OLYSIO, which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
|November 27, 2013|
|13:21 EDT||JNJ||J&J may pay $1B in medical costs under hip settlement, Bloomberg says|
Johnson & Johnson may have to pay up to $1B to insurers who covered the medical costs of removing its recalled hip implants under the settlement announced previously, says Bloomberg. Reference Link
|November 22, 2013|
|18:05 EDT||JNJ||FDA approves Olysio for treatment of Hepatitis C |
Subscribe for More Information
|07:48 EDT||JNJ||J&J picks Carlyle, Danaher group as diagnostics bidders, Reuters says|
Johnson & Johnson (JNJ) has selected a consortium of Danaher (DHR) and Blackstone Group (BX) and Carlyle Group (CG) to advance to the final stage of negotiations for Ortho Clinical Diagnostics, said Reuters yesterday, citing people familiar with the matter. These bidders appear willing to pay the most, the sources told Reuters, adding that a deal may now value the unit closer to $4B, which is less than the $5B J&J initially sought. Reference Link